As you know that I cover Biocon and I had recommended Biocon at 295 for a target of 378 (see below call) to be achieved towards the end of October 2010.
Latest company news is that Biocon, has entered into an agreement with Teleradiology Solutions to offer its TRS Clinical Trials Radiology Reporting service to Clinigene, Biocon's Clinical Research Organization. The service is provided by its team of radiologists experienced in RECIST (Response Evaluation Criteria In Solid Tumours) which adhere to the World Health Organisation measurement criteria.
By using TRS Clinical Trials Radiology Reporting service, pharmaceutical vendors, clinical research organizations and biotechnology companies can shorten their development cycle time. Teleradiology's quality-driven reporting process and technology platform has the potential to benefit biotech and pharma companies, obviating delays in the completion of clinical trials by optimizing the radiology reporting process. Clinical trials radiology is a unique service and the objective is to demonstrate the efficacy, safety and cost utility of a new therapy for regulatory approval, with the fewest patients and in the shortest time possible.
According to Kiran Mazumdar-Shaw, chairman & managing director of Biocon Ltd, to achieve our main objective of accelerating clinical research, we leverage on an adept mix of technology, experience and personal traits. Keeping in line with our mission, Teleradiology Solutions, given their impressive track record, was the partner of choice to meet our complex image analysis requirements. "The signing of this agreement further endorses Bangalore as the hub of excellence, both in Biotechnology as well as in high end healthcare delivery to the world," she added.
"For pharmaceutical and biotechnology companies involved in drug development R&D, delays in the drug development cycle can be an issue of concern. These are in part related to delays in reporting of radiologic scans that are performed to confirm that the patient under treatment has responded positively to the drug being evaluated in the clinical trial. The delays are in turn related to the worldwide shortage of radiologists, estimated to be as high as 20 per cent in some studies. We are happy to partner with Biocon and offer our services to ensure timely execution and quality evaluation for clinical trials in radiology," stated Dr Arjun Kalyanpur, MD and chief radiologists, Teleradiology Solutions.
From: Basu, Anupam
Sent: Saturday, July 24, 2010 9:00 PM
To: 'powerfulpicks@yahoogroups.co.in'
Subject: I am revising my target price for Biocon
Importance: High
As you know that I cover Biocon and I had recommended Biocon at 295 for a target of 365 to be achieved towards the end of October 2010. On July 23rd, it touched 335.70.
Biocon has had exceptionally good results in Q1 and Q2 holds greater promise. Biocon is shifting focus on emerging markets like Africa, Latin America and the middle east which gives around 20% growth on an average compared to regulated markets of developed countries, which gives growth of around 6-8%. 3 more verticals being added to their branded formulations segment – eye care, dermatology, immune-therapy & comprehensive care.
I am revising Biocon's end-October 2010 target to 378, with an upward bias (meaning that it may attain a price that is slightly higher than the target price) to account for the significant growth plans.
Moderator
Powerfulpicks
________________________________________________
INDIA'S MOST PROFITABLE VALUE INVESTMENT GROUP
http://in.groups.yahoo.com/group/powerfulpicks
From: powerfulpicks@yahoogroups.co.in [mailto:powerfulpicks@yahoogroups.co.in] On Behalf Of powerfulpicks-owner@yahoogroups.co.in
Sent: Monday, April 26, 2010 8:51 AM
To: powerfulpicks@yahoogroups.co.in
Subject: [powerfulpicks] BUY: BIOCON at 293-295
BUY: BIOCON at 293-295 for a 6 month target of 365 (around 24% upside)
No comments:
Post a Comment